Correspondence | Published:

H5N1 virus

Transmission studies resume for avian flu

Nature volume 493, page 609 (31 January 2013) | Download Citation

In January 2012, influenza virus researchers from around the world announced a voluntary pause of 60 days on any research involving highly pathogenic avian influenza H5N1 viruses leading to the generation of viruses that are more transmissible in mammals1. We declared a pause to this important research to provide time to explain the public-health benefits of this work, to describe the measures in place to minimize possible risks, and to enable organizations and governments around the world to review their policies (for example, on biosafety, biosecurity, oversight and communication) regarding these experiments.

During the past year, the benefits of this important research have been explained clearly in publications2,3,4,5,6,7 and meetings8,9,10. Measures to mitigate the possible risks of the work have been detailed11,12,13. The World Health Organization has released recommendations on laboratory biosafety for those conducting this research14, and relevant authorities in several countries have reviewed the biosafety, biosecurity and funding conditions under which further research would be conducted on the laboratory-modified H5N1 viruses10,15,16,17. Thus, acknowledging that the aims of the voluntary moratorium have been met in some countries and are close to being met in others, we declare an end to the voluntary moratorium on avian-flu transmission studies.

The controversy surrounding H5N1 virus-transmission research has highlighted the need for a global approach to dealing with dual-use research of concern. Developing comprehensive solutions to resolve all the issues will take time. Meanwhile, H5N1 viruses continue to evolve in nature.

Because H5N1 virus-transmission studies are essential for pandemic preparedness and understanding the adaptation of influenza viruses to mammals, researchers who have approval from their governments and institutions to conduct this research safely, under appropriate biosafety and biosecurity conditions, have a public-health responsibility to resume this important work. Scientists should not restart their work in countries where, as yet, no decision has been reached on the conditions for H5N1 virus transmission research. At this time, this includes the United States and US-funded research conducted in other countries. Scientists should never conduct this type of research without the appropriate facilities, oversight and all necessary approvals.

We consider biosafety level 3 conditions with the considerable enhancements (BSL-3+) as outlined in the referenced publications11,12,13 to be appropriate for this type of work, but recognize that some countries may require BSL-4 conditions in accordance with applicable standards (such as Canada). We fully acknowledge that this research — as with any work on infectious agents — is not without risks. However, because the risk exists in nature that an H5N1 virus capable of transmission in mammals may emerge, the benefits of this work outweigh the risks.


  1. 1.

    et al. Nature 481, 443 (2012).

  2. 2.

    , & Science 335, 662–663 (2012).

  3. 3.

    , & J. Infect. Dis. 205, 1628–1631 (2012).

  4. 4.

    Nature 482, 155 (2012).

  5. 5.

    & Nature 486, 332–333 (2012).

  6. 6.

    , & Nature 486, 335–340 (2012).

  7. 7.

    & Science 336, 1522–1523 (2012).

  8. 8.

    WHO. Report on Technical Consultation on H5N1 Research Issues (WHO, 2012); available at .

  9. 9.

    NSABB. Statement of the National Science Advisory Board for Biosecurity, March 2012; available at .

  10. 10.

    Agenda for Workshop on Gain-of-Function Research on Highly Pathogenic Avian Influenza H5N1 Viruses, 17–18 December 2012, Bethesda, Maryland; available at .

  11. 11.

    mBio 3, e00049–12 (2012).

  12. 12.

    et al. Nature 486, 420–428 (2012).

  13. 13.

    et al. Science 336, 1534–1541 (2012).

  14. 14.

    WHO. Guidance on risk control measures for H5N1 transmission research, July 2012; available at .

  15. 15.

    Public Health Agency of Canada. Advisory on Transmissible H5N1 Viruses, 1 February 2012; available at .

  16. 16.

    COGEM. Letter in response to influenza research at Erasmus MC (in Dutch), 21 March 2012; available at .

  17. 17.

    US Government Policy for Oversight of Life Sciences Dual Use Research of Concern (2012); available at .

Download references

Author information


  1. Erasmus Medical Center, Rotterdam, the Netherlands.

    • Ron A. M. Fouchier
  2. Icahn School of Medicine at Mount Sinai, New York, USA.

    • Adolfo García-Sastre
  3. University of Wisconsin–Madison, Wisconsin, USA, and University of Tokyo, Japan.

    • Yoshihiro Kawaoka


  1. 37 co-authors


  1. Search for Ron A. M. Fouchier in:

  2. Search for Adolfo García-Sastre in:

  3. Search for Yoshihiro Kawaoka in:

Corresponding author

Correspondence to Yoshihiro Kawaoka.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Full list of co-authors

About this article

Publication history



Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing